Content area
Full Text
Introduction: Chronic kidney disease (CKD) is associated with worsening and death from CO VID-19. COVID-19 patients with CKD who are hospitalized need antivirals and/or antibiotics that require dose adjustments [1]. Furthermore, dose adjustment for patients with CKD will decrease the adverse drug reaction, reduce the length of stay and death, and decrease therapy costs [2]. Glomerular filtration rate (GER) remains a gold standard for adjusting medication doses in CKD patients.
Aim: To evaluate the dose adjustment of antivirals and/or antibiotics and analyze its relation with therapeutic outcomes and length of stay for COVID-19 patients with CKD.
Methods: A cross-sectional study with a total sampling method was performed at a hospital in Java Island, Indonesia. All inpatients above 17 years old with COVID-19 and CKD that received antibiotics and or antiviral...